Solid Biosciences

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy (DMD). It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024. SLDB recently received additional liquidity from a PIPE investment, improving its risk-reward equation.

Buy Solid Biosciences: Unpacking Its Main Value Driver

CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to two newly hired employees. These grants were made pursuant to the Company's 2024 Inducement Stock Incentive Plan and were made as an inducement material to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.

Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug

– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 – CHARLESTOWN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for SGT-003, the company's next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate.

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.

How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback

— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 —

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Liberty Media Corp-Liberty SiriusXM

Marpai

OPKO Health

PBF Energy

The number of notable insider purchases in mid-January may have been somewhat small, but a couple from the Oracle of Omaha made headlines.

More Big Warren Buffett Purchases Highlight Recent Insider Buying

Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up

IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs market is expected to reach $27.4 billion by 2030. Solid Biosciences might be able to overcome gene therapy competitors in the DMD space with its own proprietary capsid of AAV-SLB101, which may end up having better transgene expression.

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has been granted orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for SGT-003, the company's next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate.

Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.

Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why

CHARLESTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $108.9 million private placement, which is expected to close on or about January 11, 2024, subject to the satisfaction of customary closing conditions. The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the “Minimum Price” requirement (as defined in the Nasdaq rules).

Solid Biosciences Announces $109 Million Private Placement

Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up

CHARLESTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Thursday, November 30, 2023, at 1:00 pm ET.

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

Solid Biosciences (SLDB) gains 28% as the FDA clears SGT-003, a gene therapy candidate, for clinical studies in the treatment of Duchenne Muscular Dystrophy.

Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND

– IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 – – Strengthened management team with appointment of Dr. Gabriel Brooks as CMO – – Company ends third quarter with approximately $142.9 million in cash and investments; Anticipated cash runway through multiple important pipeline milestones and into 2025 – CHARLESTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business update.

Solid Biosciences Provides Third Quarter Business Update and Financial Results

- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid's focus on both neuromuscular and cardiac diseases -

Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

Biogen

bluebird bio

BioMarin Pharmaceutical

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Novartis

Regeneron Pharmaceuticals

Sarepta Therapeutics

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘

Are Gene Therapy Stocks The Market's Next Big Winners?

CHARLESTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the following two upcoming investor conferences:

Solid Biosciences to Participate at Upcoming Investor Conferences

– On track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) –

Solid Biosciences Provides Second Quarter Business Update and Financial Results

CHARLESTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 3:00 PM ET.

Solid Biosciences to Participate at the Jefferies Healthcare Conference

CHARLESTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in a fireside chat at the Barclays Gene Editing & Therapy Summit on Wednesday, May 24, 2023 at 11:30 AM ET.

Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit

— Oral presentation highlighting data from multiple animal models demonstrated administration of AVB-202 resulted in frataxin (FXN) expression in cardiac and central nervous system (CNS) tissues with a favorable safety profile and may improve cardiac function and extend survival —

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

Solid Biosciences Inc. (SLDB) came out with a quarterly loss of $1.54 per share versus the Zacks Consensus Estimate of a loss of $1.83. This compares to loss of $3.30 per share a year ago.

Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates

– Company remains on track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) –

News for Solid Biosciences Stock (SLDB)